# Author Index


**A**bbott, Alison, Neurobiological perspectives on drugs of abuse 169
Abbott, N. Joan, *see* Revest, Patricia, A.
Abood, Mary E. and Martin, Billy R., Neurobiology of marijuana abuse 201
Alvarez, Javier, *see* García-Sancho, Javier
Azuma, Ichiro, Development of the cytokine inducer romurtide: experimental studies and clinical application 425

**B**agetta, G., Nisticò, G. and Bowery, N. G., Bagetta *et al.* reply (Letter) 14
Barnard, Eric, Will the real NMDA receptor please stand up? 11
Barnes, Peter J. and Fan Chung, K., Questions about inhaled $\beta_2$-adrenoceptor agonists in asthma 20
Bartfai, T., Fisone, G. and Langel, Ü., Galanin and galanin antagonists: molecular and biochemical perspectives 312
Baumgold, Jesse, Muscarinic receptor-mediated stimulation of adenylyl cyclase 341
Bean, Bruce P., Pharmacology and electrophysiology of ATP-activated ion channels 87
Belknap, John K., *see* Crabbe, John C.
Berlan, M., Montastruc, J-L. and Lafontan, M., Pharmacological prospects for $\alpha_2$-adrenoceptor antagonist therapy 277
Bertrand, D. *see* Changeux, J-P.
Blake, Simon, *see* Henderson, B.
Bluthé, Rose-Marie, *see* Kent, Stephen
Bock, K.W., Metabolic polymorphisms affecting activation of toxic and mutagenic arylamines 223
Bockaert, Joël R., Fozard, John R., Dumuis, Aline and Clarke, David E., The 5-$HT_4$ receptor: a place in the sun 141
Bonner, Tom I., Domains of muscarinic acetylcholine receptors that confer specificity of G protein-coupling 48
Bottari, Serge P., *see* Steckelings, U. Muscha
Bowen, Wayne D., *see* Quirion, Remi
Bowery, N.G., *see* Bagetta, G.
Branchek, T.A., *see* Hartig, P.R.
Briley, Mike and Grahame-Smith, David, 5-HT: on the psychiatrist's couch 337
Buchheit, K.H., *see* Chapman, I.D.
Bursch, Wilfried, Oberhammer, Franziska and Schulte-Hermann, Rolf, Cell death by apoptosis and its protective role against disease 245

**C**att, Kevin J., *see* Stojilkovíc, Stanko, S.
Catterall, W.A. and Streissnig, J., Receptor sites for $Ca^{2+}$ channel antagonists 256
Cavero, I., *see* Escande, D.
Changeux, J-P., Devillers-Thiéry, A., Galzi, J-L. and Bertrand, D., New mutants to explore nicotinic receptor functions 299
Chapman, I.D., Buchheit, K.H., Manley, P. and Morley, J., Active enantiomers may cause adverse effects in asthma (Letter) 231
Cholerton, Suzanne, Daly, Ann K. and Idle, Jeffrey R., The role of individual human cytochromes P450 in drug metabolism and clinical response 434
Christophe, Jean, *see* Nagata, Shigekazu
Clarke, David E., *see* Bockaert, J.R.
Clarke, Paul B.S., The fall and rise of neuronal α-bungarotoxin binding proteins 407
Clement, O., *see* Puceat, M.
Colquhoun, D., Unravelling the paradox (Letter) 429
Commeely, O.M., *see* Power, R.F.
Crabbe, John C. and Belknap, John K., Genetic approaches to drug dependence 212

**D**aly, Ann K., *see* Cholerton, Suzanne
Dantzer, Robert, *see* Kent, Stephen
Davis, Michael, The role of the amygdala in fear-potentiated startle: implications for animal models of anxiety 35
Devillers-Thiéry, A., *see* Changeux, J-P.
Di Chiara, Gaetana and North, Alan R., Neurobiology of opiate abuse 185
Di Chiara, Gaetano, Reinforcing drug seeking (Letter) 428
Doble, Adam and Martin, Ian L., Multiple benzodiazepine receptors: no reason for anxiety 76
Dougall, Iain G., *see* Leff, Paul
Dummis, Aline, *see* Bockaert, J.R.

**E**rnsberger, Paul, *see* Michel Martin C.
Escande, Denis and Cavero, Icilio, $K^+$ channel openers and 'natural' cardioprotection 269

**F**aden, Alan I. and Salzman, Steven, Pharmacological strategies in CNS trauma 29
Fan Chung, K., *see* Barnes, Peter J.
Filov, Vladimir A., *see* Lipnick, Robert L.
Fischmeister, Rodolphe, *see* Hartzell, H. Criss
Fisone, G., *see* Bartfai, T.
Flower, Rod, see Rothwell, Nancy J.
Fort, Steve, *see* Smith, Jerry A.
Fozard, John R., see Bockaert, J.R.
France, C.P., *see* Woods, J.H.
Fredholm, Bertil B., *see* Rudolphi, Karl A.
Freissmuth, Michael, *see* Schütz, Wolfgang

**G**alione, Antony, $Ca^{2+}$-induced $Ca^{2+}$ release and its modulation by cyclic ADP-ribose 304
Gall, Christine M., Regulation of brain neurotrophin expression by physiological activity 401
Galzi, J-L., *see* Changeux, J-P.
Gandy, Sam and Greengard, Paul, Amyloidogenesis in Alzheimer's disease: some possible therapeutic opportunities 108
García-Sancho, Javier, Alvarez, Javiar, Montero, Mayte and Villalobos, Carlos, $Ca^{2+}$ influx following receptor activation (Letter) 12
Gonzalez, Frank J., Human cytochromes P450: problems and prospects 346
Gottlicher, Martin, *see* Poellinger, L.
Grahame-Smith, David, *see* Briley, Mike
Granger, D. Neil, *see* Wallace, John L.
Grant, Augustus O. and Wendt, David J., Block and modulation of cardiac $Na^+$ channels by antiarrhythmic drugs, neurotransmitters and hormones 352
Green, Stephen, Nuclear receptors and chemical carcinogenesis 251
Greengard, Paul, *see* Gandy, Sam
Gustafsson, Jak-Ake, *see* Poellinger, L.

**H**amill, Owen P., Lane, John W. and McBride Jr, Don W., Amiloride: a molecular probe for mechanosensitive channels 373
Harper, Diane, *see* Leff, Paul
Harris, R.A. and Samson, H.H., Reply (Letter) 430
Harris, R. Adron, *see* Samson, Herman H.
Hartig, Paul R., Branchek, Theresa A. and Weinshank, Richard L., A subfamily of 5-$HT_{1D}$ receptor genes 152
Hartig, Paul R., *see* Uhl, George R.
Hartzell, H. Criss and Fischmeister, Rodolphe, Direct regulation of cardiac $Ca^{2+}$ channels by G proteins: neither proven nor necessary 380
Häussinger, Dieter and Lang, Florian, Cell volume and hormone action 371
Hay, Alastair, Scientific discourse, in public 233
Hen, R., Of mice and flies: commonalities among 5-HT receptors 160
Henderson, Brian and Blake, Simon, Therapeutic potential of cytokine manipulation 145
Higgins, Guy A., *see* Sellers, Edward M.
Horwitz, S.B., Mechanism of action of taxol 134
Huffman, William F., *see* Nichols, Andrew J.

**I**dle, Jeffrey, R., *see* Cholerton, Suzanne

Ishihara, Takeshi, *see* Nagata, Shigekazu
Itzhak, Yossef, *see* Quirion, Remi
Izquierdo, Ivan, Dopamine receptors in the caudate nucleus and memory processes 7

**J**akobs, K.H., *see* Lacombe, M.L.
Jefferys, John G.R., Mechanism of tetanus toxin in neuronal cell death (Letter) 13
Johnson, Eric F., Mapping determinants of the substrate selectivities of P450 enzymes by site-directed mutagenesis 122
Johnson, Kenneth M., *see* Woolverton, W.L.
Juliano, R.L., *see* Kornberg, L.
Junien, Jean-Louis, *see* Quirion, Remi

**K**elley, Keith W., *see* Kent, Stephen
Kent, Stephen, Bluthé, Rose-Marie, Kelley, Keith W. and Dantzer, Robert, Sickness behavior as a new target for drug development 24
Koob, George F., Drugs of abuse: anatomy, pharmacology and function of reward pathways 177
Kornberg, L. and Juliano, R.L., Signal transduction from the extracellular matrix: the integrin-tyrosine kinase connection 93
Kossmann, T., *see* Morganti-Kossmann, M.C.

**L**acombe, M.L. and Jakobs, K.H., Nucleoside diphosphate kinases as potential new targets for control of development and cancer 46
Lafontan, M., *see* Berlan, M.
Lambert, Jeremy J., *see* Peters, John A.
Lane, John W., *see* Hamill, Owen P.
Lang, Florian, *see* Häussinger, Dieter
Langel, Ü., *see* Bartfai, T.
Leff, Paul, Dougall, Iain G. and Harper, Diane, Deviations from receptor theory? (Letter) 54
Lewis, Malcolm J., *see* Smith, Jerry A.
Libert, Frederick, *see* Nagata, Shigekazu
Lipnick, Robert L. and Filov, Vladimir A., Nikolai Vasilyevich Lazarev, toxicologist and pharmacologist comes in from the cold 56
Lummis, S., Endogenous bacterial receptors should cause anxiety (Letter) 232

**M**acLennan, David H., The genetic basis of malignant hyperthermia 330
Malliani, Alberto, *see* Pagani, Massimo
Malone, Hilary M., *see* Peters, John A.
Manley, P., *see* Chapman, I.D.
Martin, Billy R., *see* Abood, Mary E.
Martin, Ian L., *see* Doble, Adam
Masaki, Tomoh, *see* Sakuri, Takeshi
Marullo, Stefano, *see* Strosberg, A. Donny
Max, B., This and That: the essential pharmacology of herbs and spices 15
Max, B., This and That: creatine's superfluous methyl and the shadowed art of Cimabue 99
Max, B., This and That: sequential theories for stomach cancer and the multiple applications of isotopic ratios 136
Max, B., This and That: hair pigments, the hypoxic basis of life and the Virgilian journey of the spermatozoon 272
Max, B., This and That: an artefactual alkaloid and its peptide analogs 341
McBride Jr, Don W., *see* Hamill, Owen P.
McCall, Thérèse and Vallance, Patrick, Nitric oxide takes centre-stage with newly defined roles 1
McMillan, R.M. and Walker, E.R.H., Designing therapeutically effective 5-lipoxygenase inhibitors 323
Michel, Martin C. and Ernsberger, Paul, Keeping an eye on the I site: imidazoline-preferring receptors 369
Miller, Richard J., *see* Philipson, Louis H.
Mills, Ann, Dopamine: From Cinderella to Holy Grail 399
Mitchell, J.F., BPS 150th anniversary 370
Monsma Jr, Frederick, J., *see* Sibley, David R.
Montastruc, J-L., *see* Berlan, M.
Montero, Mayte, *see* García-Sancho, Javier
Morganti-Kossmann, M.C., Kossmann, T. and Wahl, S.M., Cytokines and neuropathology 286
Morley, J., *see* Chapman, I.D.
Moskowitz, M.A., Neurogenic versus vascular mechanisms of sumatriptan and ergot alkaloids in migraine 307
Mulder, G.J., Pharmacological effects of drug conjugates: is morphine 6-glucuronide an exception? 302
Musacchio, José M., *see* Quirion, Remi

**N**agata, G.S., Ishihara, T., Robberecht, P., Libert, F., Parmetier, M., Christophe, J. and Vassart, G., RDC1 may not be VIP receptor (Letter) 102
Narahashi, T., Nerve membrane $Na^+$ channels as targets of insecticides 236
Navarra, P., *see* Preziosi, P.
Nichols, Andrew J., Ruffolo Jr, Robert R., Huffman, William F., Poste, George and Samanen, James, Development of GPIIb/IIIa antagonists as antithrombotic drugs 413
Nisticò, G., *see* Bagetta, G.
North, Alan R., *see* Di Chiara, G.

**O**'Malley, B.W., *see* Power, F.F.
Oberhammer, Franziska, *see* Bursch, Wilfried

**P**agani, Massimo, Rimoldi, Ornella and Malliani, Alberto, Low-frequency components of cardiovascular variabilities as markers of sympathetic modulation 50
Parente, L., *see* Preziosi, P.
Parkinson, Fiona E., *see* Rudolphi, Karl A.
Parmetier, Marc, *see* Nagata, G.S.
Peters, John A., Malone, Hilary M. and Lambert, Jeremy J., Recent advances in the electrophysiological characterization of 5-$HT_3$ receptors 391
Philipson, Louis H. and Miller, Richard J., A small $K^+$ channel looms large 8
Poellinger, L., Gottlicher, M. and Gustafsson, J-A., The dioxin and peroxisome proliferator-activated receptors: nuclear receptors in search of endogenous ligands 241
Pongs, Olaf, Structural basis of voltage-gated $K^+$ channel pharmacology 359
Poste, George, *see* Nichols, Andrew J.
Power, R.F., Conneely, O.M. and O'Malley, B.W., New insights into activation of the steroid hormone receptor superfamily 318
Preziosi, P., Welcome to IUTOX 222
Preziosi, P., Parente, L. and Navarra, P., Cytokines and eicosanoids in cancer drug toxicity 226
Pucéat, G., Terzic, A., Clément, O., Scamps, F., Vogel, S.M. and Vassort, G., Cardiac $\alpha_1$-adrenoceptors mediate positive inotropy via myofibrillar sensitization 263

**Q**uirion, Rémi, Bowen, W.D., Itzhak, Y., Junien, J-L., Musacchio, J.M., Rothman, R.B., Su, T-P., Tam, S. William and Taylor, D.P., A proposal for the classification of sigma binding sites 85

**R**evest, Patricia A. and Abbott, N. Joan, Membrane ion channels of endothelial cells 404
Reynolds, Gavin P., Developments in the drug treatment of schizophrenia 116
Rimoldi, Ornella, *see* Pagani, Massimo
Robberecht, Patrick, *see* Nagata, Shigekazu
Roberts, G.W., *see* Royston, M. Claire
Rothman, Richard B., *see* Quirion, Remi
Rothwell, Nancy J. and Flower, Rod, Lipocortin-1 exhibits novel actions, providing clinical opportunities 45
Rothwell, Nancy J., *see* Royston, M. Claire
Royston, M.C., Rothwell, N.J. and Roberts, G.W., Alzheimer's disease: pathology to potential treatments 131
Rudolphi, Karl A., Schubert, Peter, Parkinson, Fiona E. and Fredholm, Bertil B., Neuroprotective role of adenosine in cerebral ischaemia 439
Ruffolo Jr, Robert R., *see* Nichols, Andrew J.

**S**akuri, T., Yanagisawa, M. and Masaki, T., Molecular characterization of endothelin receptors 103
Salzman, Steve, *see* Faden, Alan I.
Samanen, James, *see* Nichols, Andrew J.
Samson, Herman H. and Harris, R. Adron, Neurobiology of alcohol abuse 206
Scamps, F., *see* Puceat, M.
Schubert, Peter, *see* Rudolphi, Karl A.
Schulte-Hermann, R., *see* Bursch, W.
Schütz, Wolfgang and Freissmuth, Michael, Reverse intrinsic activity of antagonists on G protein-coupled receptors 376
Seeberg, P.H., *see* Sommer, B.
Sellers, Edward M., Higgins, Guy A. and Sobell, Mark B., 5-HT and alcohol abuse 69
Shah, Ajay M., *see* Smith, Jerry A.
Sibley, David R and Monsma Jr, Frederick J., Molecular biology of dopamine receptors 61
Siegers, C-P., Anthranoid laxatives and colorectal cancer 229
Sieghart, Werner, $GABA_A$ receptors: ligand-gated $Cl^-$ ion channels modulated by multiple drug-binding sites 446
Smith, Jerry A., Shah, A.M., Fort, S. and Lewis, M.J., The influence of endocardial endothelium on myocardial contraction 113
Sobell, Mark B., *see* Sellers, Edward M.
Sommer, B. and Seeberg, P.H., Glutamate receptor channels: novel properties and new clones 291
Steckelings, U. Muscha, Bottari, Serge P. and Unger, Thomas, Angiotensin receptor subtypes in the brain 365
Stojilkovíc, Stanko S. and Catt, Kevin J., Neuroendocrine actions of endothelins 385
Stolerman, I., Drugs of abuse: behavioural principles, methods and terms 170
Stolerman, Ian, Reply (Letter) 429
Streissnig, J., *see* Catterall, W.A.
Strosberg, A.D. and Marullo, S., Functional expression of receptors in microorganisms 95
Su, Tsung-Ping, *see* Quirion, Remi
Swillens, Stéphane, How to estimate the total receptor concentration when the specific radioactivity of the ligand is unknown 430

**T**am, S. William, *see* Quirion, Remi
Taylor, Duncan P., *see* Quirion, Remi

Terzic, A., *see* Puceat, M.
Timmerman, H., Cloning of the $H_1$ histamine receptor 6
Triggle, D.J., Albrecht Fleckenstein (1917–1992) 265

**U**hl, George R. and Hartig, Paul R., Transporter explosion: update on uptake 421
Ungar, Thomas, *see* Steckelings, U. Muscha

**V**allance, Patrick, *see* McCall, Thérèse
Vassart, Gilbert, *see* Nagata, Shigekazu
Vassort, G., *see* Puceat, M.
Villalobos, Carlos, *see* García-Sancho, Javier
Vogel, S.M., *see* Puceat, M.

**W**ahl, S.M., *see* Morganti-Kossmann, M.C.
Wainwright, Cherry L., Myocardial preconditioning as the heart's self-protecting response against the consequences of ischaemia 90
Walker, E.R.H., *see* McMillan, R.M.
Wallace, John L. and Granger, D. Neil, Pathogenesis of NSAID gastropathology: are neutrophils the culprits? 129
Watling, K.J., Nonpeptide antagonists herald new era in tachykinin research 266
Weinshank, R.L., *see* Hartig, P.R.
Wendt, David J., *see* Grant, Augustus, O.
Winger, G., *see* Woods, J.H.
Woods, J.H., Winger, G. and France, C.P., Use of *in vivo* apparent $pA_2$ analysis in assessment of opioid abuse liability 282
Woolverton, William L. and Johnson, Kenneth M., Neurobiology of cocaine abuse 193

**Y**anagisawa, Masashi, *see* Sakuri, Takeshi

**Z**binden, G., The three eras of research in experimental toxicology 221

# Subject Index

compiled by Sara Firman

## (L) Letters


**A**becarnil 79
acetylation, and toxicity 223
acetylcholine 405
adenosine, and cerebral ischemia 90, 439
adenosine receptors 90, 440
adenylyl cyclase 339
$\alpha_1$-adrenoceptor agonists 263
β-adrenoceptor agonists 380
$\beta_2$-adrenoceptor agonists, and asthma 20, 331 (L)
$\alpha_2$-adrenoceptor antagonists 227
β-adrenoceptor antagonists 436
agonism 54 (L)
AIDS 286
alcohol abuse 69, 206, 429 (L)
alkaloids 307, 341
allethrin 236
alpidem 80
Alzheimer's disease 108, 131
amiloride 373
AMPA receptors 291
amphetamine 177
β/A4 amyloid 108, 131
amyloid precursor protein (APP) 108, 131
anaesthesia 330
androgens 253
angiotensin II receptors 365
annexin-1 (lipocortin-1) 45
antagonists, and G protein-coupled receptors 376
anthranoids 229
antiarrhythmics 352, 435
anticancer drugs 226
antidepressants 337, 437
antioxidants 29
antipsychotics 116
antithrombotics 413
anxiety 35, 337
anxiolytics 35
AP-1 DNA-binding protein 402
apoptosis 245
aprikalim 269
arachidonate metabolism modulators 29
arginine 5
arylamines (aromatic amines) 223
ascorbic acid (vitamin C) 30
aspirin 129
asthma 20, 231 (L)
ATP receptors ($P_2$ purinoceptors) 88
ATP-activated channels 87
atropine 31
avermectin B1a sites ($GABA_A$ receptors) 448

**B**arbiturate sites ($GABA_A$ receptors) 447
BayK8644 381, 405
BE18257B 106
behaviour, drug-seeking 170, 428 (L)
behaviour, sickness 24
benzodiazepine receptors 76
benzothiazepine sites 256
betaine transporters 422
$BH_4$ (tetrahydrobiopterin) 5
BIMU1 141
BIMU8 141
bradykinin 92, 315, 405
brain-derived neurotrophic factor (BDNF) 401
α-bungarotoxin binding proteins 407
buspirone 36
BW755C 325
BWA4C 326
BWB218C 326

**c**-*fos* 307
$Ca^{2+}$
and ATP-activated channels 88
intracellular levels 12 (L), 263, 304, 330, 385, 404, 443
$Ca^{2+}$ antagonists (*see also named drugs*) 29, 256
$Ca^{2+}$ channels 380
and alcohol 207
and opioid peptides 186
cADP-ribose 304
caffeine 441
calcitonin gene-related peptide (CGRP) 307
cancer
and nucleoside diphosphate kinases 46
of the stomach 136
(*see also* anticancer drugs; apoptosis; carcinogens)
cancer therapy, romurtide 425
cannabinoid receptors 201
cannabis 201
carbetapentane 85
β-carbolines 36, 76
carbon isotopes 138
carcinogens
anthranoids 229
arylamines (aromatic amines) 223
nongenotoxic 251
cardiovascular disorders, preconditioning phenomenon 90, 269
cardiovascular variabilities, measurement of 50
β-casomorphins 341
catecholamines 31
cell volume, and hormones 371
CG3509 33
CG3703 33
CGP42112A 365
CGRP (calcitonin gene-related peptide) 307
charybdotoxin (CTX) sites 361
chicken ovalbumin upstream promoter transcription factor (COUP-TF) 319
chimeric (bireceptor-recognizing) peptides 316
chlorozoxazone 438
chocolate 343
ciprostene 31
cisapride 141
CL218872 76
$Cl^-$ channels 446
clofilium 8
clonidine 36, 369
clonidine-displacing substance (CDS) 369
clozapine 119
cocaine 177, 193, 424
codeine 437
colony-stimulating factors 145
conjugates (of drugs) 302
corticosteroids 5, 20, 29
corticosterone 412
corticotropin-releasing factor (CRF) 26
coumarin 438
COUP-TF (chicken ovalbumin upstream promoter transcription factor) 319
CP93129 308
CP96345 266
creatine 99
CRF (corticotropin-releasing factor) 26
cromakalim 269
cyclic ADP-ribose 304
CYP families (P-450s) 122, 346, 434
cytochrophin 343
cytokine inducer (romurtide) 425
cytokines
and cancer drugs 226
and neuropathology 286
and sickness behaviour 24
therapeutic potential 145
(*see also named types*)

**D**AU6215 142
DAU6285 142
DDT 236
deltamethrin 236
dendrotoxin (DTX) sites 361
dextromethorphan 85, 437
diacylglycerol 385
diazepam 36
dihydroergotamine 307
dihydropyridine receptors 256, 381
dioxin 251
dioxin receptors 241, 251
dipropylcyclopentylxanthine (DPCPX) 441
disulfiram 69
dizocilpine (MK801) 34
DNA-binding protein AP-1 402
dopamine
and drug abuse 177, 188, 193, 207
and startle 36
and steroid receptors 318
dopamine receptors 61, 399
and memory ($D_2$) 7
and schizophrenia 116

dopamine transporters 421
Down syndrome 131
DPCPX (dipropylcyclopentylxanthine) 441
drug abuse
  behaviour analysis 170, 428 (L)
  pharmacogenetics 212
  reward pathways 177
  (*see also* alcohol abuse; cocaine; marijuana; opiate/opioid abuse)
drug conjugates 302
DTG (ditolylguanidine) 85

**E**DRF (endothelium-derived relaxing factor) 1, 92, 113, 406
eicosanoids 226
encainide 435
endocardin 113
endothelial ion channels 404
endothelin receptors 103, 385
endothelium-derived relaxing factor (EDRF) 1, 92, 113, 406
ergot alkaloids 307
estrogen receptor related (ERR) proteins 319
estrogens 251
ethanol 69, 177, 206, 429 (L)
exorphins 341

**F**ear-potentiated startle 35
fenoterol 21, 231 (L)
fenthion 233
FLAP (5-lipoxygenase activating protein) 324
flecainide 435
Fleckenstein, A. 265
foods
  exorphin-containing 341
  toxic 16, 136
formoterol 23, 231 (L)
Fos protein 338, 402
free-radical scavengers 29
frescoes, pigments used 101

**G** protein-coupled receptors, and antagonists 376
G proteins 339, 380
$GABA_A$ receptors 76, 177, 207, 446
GABA transporters 422
galanin 312, 338
gangliosides 29
glucagon 371
glucocorticoids 228
glucose transporters 423
glucuronides 302
glutamate, and schizophrenia 121
glutamate receptors 291
glutamate transporters 423
gluten exorphin 342
glycine transporters 422
GPIIb/IIIa antagonists 413
GR67330 395
growth factors 145
GTP-binding proteins, and nucleoside diphosphate kinases 46
guanine nucleotides, and antagonist binding 377

**H**A966 121
hair pigments 275
haloperidol 85, 116
hazardous waste 233
head injuries *see* traumatic CNS injuries
hemorphin 343
herbs 15
histamine 405
histamine $H_1$ receptors 6
HIV infection 286
hormones
  and cell volume 371
  and toxicants 226
5-HT receptors 160
$5\text{-HT}_{1B}$ receptors 307
$5\text{-HT}_{1D}$ receptors 152, 307
$5\text{-HT}_2$ receptors 119
$5\text{-HT}_3$ receptors 119, 207
$5\text{-HT}_4$ receptors 141
5-HT (5-hydroxytryptamine)
  and alcohol abuse 69
  and CNS trauma 31
  and psychiatric disorders 337
  and startle 36
5-HT transporters 421
hydroxynitrobenzylthioguanosine (NBTG) 442
hydroxyurea 228
hyperthermia, malignant 330

$\mathbf{I}_{K,S}$ channel 8
I site 369
ibuprofen 31
ICI154129 377
ICI174864 377
ICI207968 325
ICI211965 327
ICI216800 328
ICID2138 327
ICS205930 142, 392
idazoxan 369
imidazoline receptors 369
infection, and sickness behaviour 24
inositol 1,4,5 triphosphate ($IP_3$) 304, 385
insecticides 236
insulin 371
integrins 93
intercrines 145
interferons 145
interleukin-1 (IL-1) 24, 132, 145, 227, 286
interleukin-6 (IL-6) 145, 227, 287
$IP_3$ 304, 385
isoprenaline 20, 231 (L), 381
isotopic ratios 136

**K**$^+$ channel openers 269
$K^+$ channels 8, 92, 186, 359, 404
kainate receptors 291

**L**axatives, anthranoids 229
Lazarev, N. V. 56
lead white 101
leukotrienes 323
lidocaine 353
lipocortin-1 (annexin-1) 45
5-lipoxygenase activating protein (FLAP) 324
5-lipoxygenase inhibitors 323
losartan (DuP753) 365
$LTB_4$ 323

**M**alignant hyperthermia 330
marijuana 201
MDL72222 392
mechanosensitive (transducer) channels 373, 406
meclofenamic acid 31
melanins 275
memory, and dopamine $D_2$ receptors 7
mephenytoin 438
methylprednisolone 29
metoclopramide 141
metoprolol 437
mexiletine 435
microbial expression systems 95, 232 (L)
midazolam 438
migraine 307
milk proteins 341
minoxidil sulfate 303
mitogens 245
MK801 (dizocilpine) 34
monoamine modulators 29
monoamine transporters 423
morphine 36, 341, 437
morphine 6-glucuronide 302
MR2266 377
muramyldipeptide (romurtide) 425
muscarinic acetylcholine receptors 48, 339

**N**a$^+$ channels
  and antiarrhythmic drugs 352
  and insecticides 236
nalbuphine 285
nalmefene 31
naloxone 31, 85, 377
NBTG (hydroxynitrobenzylthioguanosine) 442
NBTI (nitrobenzylthioinosine) 442
nerve growth factor (NGF) 401
neuroleptics 437
neurotoxins 424
neurotransmitter transporters 421
neurotrophin 3 (NT-3) 401
neurotrophins 401
neutrophils 129
nicorandil 269
nicotinic acetylcholine receptors 89, 207, 299, 407
nifedipine 438
nitrendipine 405
nitric oxide 1, 92, 113, 406
nitric oxide synthase 1
nitrobenzylthioinosine (NBTI) 442
nitrosamines 137
nitrovasodilators 5
NMDA antagonists 29
NMDA receptors 11, 121, 291, 403
NO synthase 1
nonelectrolytes 56
noradrenaline 120
noradrenaline transporters 421
norbinaltorphimine 31
NSAIDs (nonsteroidal anti-inflammatory drugs) 129
nucleoside diphosphate kinases 46

**O**lfaction 18
ondansetron 392
opiate/opioid abuse 177, 185, 282
μ-opioid agonists 302
opioid antagonists 29, 377
opioid receptors 185
orphan receptors 102 (L), 152, 319
oxygen, and life 272

$\mathbf{P}_2$ purinoceptors 88
P-450 12 (L), 122, 241, 346, 434
PAF (platelet-activating factor) 405
PAF (platelet-activating factor) antagonists 29
partition coefficients 56
PD123177 365
PDGF (platelet-derived growth factor) 287
pentazocine 85
pentostatin 442
peptidoleukotrienes 323
peroxisome proliferator-activated receptors (PPAR) 241, 251, 320
peroxisome proliferators 251
perphenazine 437
pharmacogenetics 212, 348
phenacetin 438
phenidone 325
phenobarbital 438
phenycyclidine 121
phenylalkamine sites 256
R-phenylisopropyladenosine (R-PIA) 92, 441
pheromone receptors 97
phosphagens 99
phosphorylcreatine 99
R-PIA (R-phenylisopropyladenosine) 92, 441
picrotoxinin/TBPS sites ($GABA_A$ receptors) 447
pigments
  in frescoes 101
  hair 275

pinacidil 269
piperoxan 36
platelet-activating factor (PAF) 405
platelet-activating factor (PAF) antagonists 29
platelet-derived growth factor (PDGF) 287
porcine stress syndrome 330
(+)-3-PPP 85
proline transporters 423
propafenone 435
propentofylline 442
prostacyclin 92
prostaglandins 26, 129
protein kinase C 339
pyrethroids 236

Quadazocine 31
quantitative trait loci (mapping) 216
quinidine 435

RCD4 152
RDC1 102 (L)
RDC4 152
reactive blue 2 (dye) 88
receptoroids *see* orphan receptors
receptors
  binding studies 430
  classification 154
  expression systems 95, 232 (L)
  (*see also named receptors*)
renzapride 141
REV5901 328
reward pathways (drug abuse) 177, 185
RGD (peptide sequence) 414
rhodopsin receptors 385
RNA editing 295
Ro154513 78
Ro54864 sites ($GABA_A$ receptors) 448
romurtide 425
RP52891 (nicorandil) 269
RP67580 266
ryanodine receptors 330
*RYR1* 330

Salbutamol 21, 231 (L)
salmeterol 21, 231 (L)
SC38249 12 (L)
SCH23390 188
schizophrenia 116, 342
scopolamine 31
SDZ205557 142
sickness behaviour 24
sigma (σ) sites 85, 120
SK&F10047 85
SK&F106760 414
SK&F107260 414
SK&F96365 12 (L)
spantide 315
specific 5-HT reuptake inhibitors (SRIs) 337
spermatozoa, and oxygen 273
spices 15
SR48968 266
SRIs (specific 5-HT reuptake inhibitors) 337
startle, fear-potentiated 35
steroid receptor reporting systems 98
steroid receptors 252, 318
steroid sex hormones 252
steroid sites ($GABA_A$ receptors) 447
steroid sulfates 303
steroids
  and asthma 20
  and neurotrauma 29
substance P 315
sudden infant death syndrome (SIDS) 342
sulpiride 119
sumatriptan 152, 307
synapses, and drugs 207, 429 (L)

Tachykinin antagonists 266
tamoxifen 249
taurine transporters 423
taxol 134
TCDD *see* dioxin
terbutaline 23, 231 (L)
testosterone 253
tetanus toxoid 13 (L)
tetraethylammonium (TEA) sites 361
tetrahydrobiopterin ($BH_4$) 5
tetrodotoxin (TTX) 394
TGF-β 250, 288
theophylline 441
thioridazine 437
thrombin 405
thymopoietin 412
thyrotropin-releasing hormone (TRH) 29
timolol 437
tirilazad 30
TNF-α 145, 286
α-tocopherol (vitamin E) 30
toxic foods 16
toxicology
  publicity 233
  research history 221
transforming growth factor β (TGF-β) 250, 288
transporters 421
traumatic CNS injuries 29, 131, 286, 307
triazolam 438
tricyclic antidepressants 437
tropanserin (MDL72222) 392
tropisetron (ICS205930) 142, 392
(+)-tubocurarine 392
tumour necrosis factor α (TNF-α) 145, 286
tyrosine kinases 93, 151

U63447A 31

Vesicular transporters 423
VIP receptors 102 (L)

Warble flies 233
WIN51708 266
WIN62577 266
WY50295 328

Yeast expression reporter systems 97
YM14673 33
yohimbine 36, 277

Zacopride 141
zileuton 326
$Zn^{2+}$ sites ($GABA_A$ receptors) 448
zolpidem 77